Fidaxomicin, a macrolide antibiotic, is noninferior to vancomycin in the treatment of Clostridium difficile diarrhea in terms of clinical cure. This was the main finding of a recent randomized trial that sought to demonstrate the noninferiority of fidaxomicin for this indication. C difficile, which causes 15% to 25% of antibiotic-associated…
Read more »
Proton-pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea (CDAD). Doctors and patients are being warned that if a patient develops diarrhea that does not improve while receiving a PPI, then CDAD should be considered as a diagnosis and managed appropriately, according to an advisory…
Read more »
indicates a Peer-Reviewed Article
Doxycycline may provide significant protection against Clostridium difficile infections
Hospitalized patients who receive doxycycline in addition to ceftriaxone have a 79% reduced risk of Clostridium difficile infection vs patients who receive ceftriaxone only, a recent study found. “In India, the true prevalence of [C. difficile] is not known because a majority of the hospitals do not investigate for this…
Read more »